The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2025
Real-world use of antispasmodic drugs during IUD insertion - insights from the large observational study EURAS-LCS12.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eggebrecht Lisa, Rizzo Manuel, Klinghardt Moritz, Böhnke Tanja, Barnett Clare, Heinemann Klaas
Аннотация
INTRODUCTION: Antispasmodic drugs are used to facilitate the insertion of intrauterine devices (IUD), and to decrease uterine cramping during the procedure. Evidence supporting these benefits is scarce, and little is known about the prevalence of antispasmodic use before IUD insertion.
METHODS: EURAS-LCS12 is an ongoing non-interventional cohort study in ten European countries. Information is gathered from health care professionals (HCP) and IUD users via questionnaires at the time of IUD insertion. Patterns of antispasmodics before IUD insertion, by participating country, were assessed using descriptive methods.
RESULTS: 96,024 users were included in the study, of which 2.7% (N = 2,565) received antispasmodics before IUD insertion, with notable differences observed between countries. Highest antispasmodic use was observed in France and Germany: in France, almost 50% of HCPs (68/144) gave antispasmodics at least once during the study period. In Germany, 16% of enrolling HCPs used antispasmodics at least once during the study period; two HCPs (0.8%) administered antispasmodics in 69% of all study participants.
CONCLUSION: Clinical practices for prescribing and administering antispasmodics during IUD insertion vary by country and seem to rely on local recommendations, or locally applicable best practices. The heterogeneous use of antispasmodics with uncertain benefits highlights the need for evidence-based recommendations.
METHODS: EURAS-LCS12 is an ongoing non-interventional cohort study in ten European countries. Information is gathered from health care professionals (HCP) and IUD users via questionnaires at the time of IUD insertion. Patterns of antispasmodics before IUD insertion, by participating country, were assessed using descriptive methods.
RESULTS: 96,024 users were included in the study, of which 2.7% (N = 2,565) received antispasmodics before IUD insertion, with notable differences observed between countries. Highest antispasmodic use was observed in France and Germany: in France, almost 50% of HCPs (68/144) gave antispasmodics at least once during the study period. In Germany, 16% of enrolling HCPs used antispasmodics at least once during the study period; two HCPs (0.8%) administered antispasmodics in 69% of all study participants.
CONCLUSION: Clinical practices for prescribing and administering antispasmodics during IUD insertion vary by country and seem to rely on local recommendations, or locally applicable best practices. The heterogeneous use of antispasmodics with uncertain benefits highlights the need for evidence-based recommendations.